Moreover, they demonstrated that in xenograft mouse models infused with SCLC cell lines, CD56 expression facilitated tumor-cell killing, since mice bearing CD56+ tumors experienced a considerable reduction in tumor burden after 20 days after tumor-cell injection and an increased OS, suggesting a potential immunotherapeutic approach for CD56+ SCLC. Here, NCAM1 is linked to neoplasm.